NCT04818632: AZD9833 China PK Study

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Endocrine (Hormone) Therapy, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 130 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with previous treatment of AZD9833; Patients with uncontrolled central nervous system (CNS) metastasis

Comments are closed.

Up ↑